Imatinib found beneficial for DFSP in systematic review

  • Navarrete-Dechent C & al.
  • JAMA Dermatol
  • 2 janv. 2019

  • Par Brian Richardson, PhD
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • A systematic review suggests that imatinib is associated with a >60% response rate for patients with locally advanced or metastatic dermatofibrosarcoma protuberans (DFSP).
  • ~55% of patients achieved a partial response.

Why this matters

  • Existing data on the optimal dose and effectiveness of imatinib are limited and variable.

Key results

  • The complete response rate was 5.2%.
  • The partial response rate was 55.2%.
  • The stable disease rate was 27.6%.
  • The progression rate was 9.2%.
  • 400- and 800-mg daily doses of imatinib were associated with similar response rates (67.5% vs 67.1%; P>.99).
  • 60.3% of patients underwent surgery after imatinib.
  • 73.5% of patients experienced adverse events, with 15.1% experiencing grade 3/4 adverse events.

Study design

  • 9 studies with 152 patients treated with imatinib as monotherapy or as adjuvant/neoadjuvant therapy to surgery were included in the systematic review.
  • Funding: National Cancer Institute/NIH.

Limitations

  • Heterogeneity between included studies.
  • Moderate/high risk for bias in included studies.